• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗最难治疗的患者:重新定义住院作为开始丙型肝炎治疗的机会。

Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment.

机构信息

Department of Medicine, VA Palo Alto Health Care System, 3801 Miranda Ave (111), Palo Alto, CA, 94304, USA.

Pharmacy Service, VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA, 94304, USA.

出版信息

Dig Dis Sci. 2022 Apr;67(4):1244-1251. doi: 10.1007/s10620-021-06941-3. Epub 2021 Mar 26.

DOI:10.1007/s10620-021-06941-3
PMID:33770327
Abstract

BACKGROUND

Chronic hepatitis C (CHC) is traditionally treated in the outpatient setting. Despite the excellent tolerability, shortened treatment duration, and high cure rates of newer direct-acting antivirals (DAAs), many vulnerable patients remain untreated due to issues with linkage to care.

AIMS

This study sought to reframe and establish the hospital admission as a unique opportunity to initiate antiviral treatment for patients with CHC, particularly those with psychosocial or linkage to care issues.

METHODS

Patients with untreated CHC were identified either on the Psychiatry or Med/Surg wards at the Veterans Affairs Palo Alto Health Care System (VAPAHCS). If found to be appropriate for treatment initiation, patients were started on antivirals during their hospitalization and followed closely while inpatient and after discharge to assess for sustained virologic response (SVR), treatment tolerability, and treatment completion.

RESULTS

Overall, 36% (23) of potential treatment candidates were initiated on DAA treatment during their hospitalization. Of these patients, 91.3% had documented treatment completion with an intention-to-treat and modified intention-to-treat SVR rate of 91.3% and 100%, respectively.

CONCLUSIONS

We establish the hospital admission as a valuable opportunity for HCV treatment initiation, yielding excellent treatment outcomes in those who would not otherwise be treated and achieved a modified intention-to-treat response rate of 100%.

摘要

背景

慢性丙型肝炎(CHC)传统上在门诊环境中治疗。尽管新型直接作用抗病毒药物(DAA)具有极好的耐受性、缩短了治疗时间和高治愈率,但由于与护理衔接的问题,许多弱势患者仍未得到治疗。

目的

本研究旨在重新构建并确立住院治疗作为为 CHC 患者启动抗病毒治疗的独特机会,特别是那些存在心理社会或与护理衔接问题的患者。

方法

在退伍军人事务帕洛阿尔托医疗保健系统(VAPAHCS)的精神病科或内科/外科病房发现未经治疗的 CHC 患者。如果发现适合开始治疗,患者将在住院期间开始接受抗病毒药物治疗,并在住院期间和出院后密切随访,以评估持续病毒学应答(SVR)、治疗耐受性和治疗完成情况。

结果

总体而言,23%(23 例)有治疗潜力的患者在住院期间开始接受 DAA 治疗。在这些患者中,91.3%有记录表明完成了治疗,意向治疗和改良意向治疗的 SVR 率分别为 91.3%和 100%。

结论

我们将住院治疗确立为 HCV 治疗启动的宝贵机会,为那些原本无法接受治疗的患者带来了极好的治疗结果,并实现了改良意向治疗的 100%应答率。

相似文献

1
Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment.治疗最难治疗的患者:重新定义住院作为开始丙型肝炎治疗的机会。
Dig Dis Sci. 2022 Apr;67(4):1244-1251. doi: 10.1007/s10620-021-06941-3. Epub 2021 Mar 26.
2
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.直接作用抗病毒治疗慢性丙型肝炎和肝细胞癌患者的持续病毒学应答:系统评价和荟萃分析。
J Hepatol. 2019 Sep;71(3):473-485. doi: 10.1016/j.jhep.2019.04.017. Epub 2019 May 13.
3
Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.直接作用抗病毒药物治疗丙型肝炎病毒时,住院患者与未住院患者的持续病毒学应答。
Ann Pharmacother. 2021 May;55(5):565-574. doi: 10.1177/1060028020964117. Epub 2020 Oct 5.
4
Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.瑞士慢性丙型肝炎直接抗病毒治疗的卓越成果。
Swiss Med Wkly. 2018 Jan 18;148:w14560. doi: 10.4414/smw.2018.14560. eCollection 2018.
5
Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system.在退伍军人事务医疗系统中,6 周或更短时间的直接作用抗病毒治疗慢性丙型肝炎的持续病毒学应答:经验。
J Gastroenterol Hepatol. 2019 Dec;34(12):2173-2178. doi: 10.1111/jgh.14703. Epub 2019 Jun 18.
6
Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.直接作用抗病毒药物治疗慢性丙型肝炎的真实世界经验。
J Viral Hepat. 2020 Feb;27(2):195-204. doi: 10.1111/jvh.13218. Epub 2019 Nov 11.
7
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.在公共医疗保健环境中,使用通用直接作用抗病毒药物进行去中心化护理,以管理慢性丙型肝炎。
J Hepatol. 2019 Dec;71(6):1076-1085. doi: 10.1016/j.jhep.2019.07.006. Epub 2019 Jul 17.
8
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.正在接受药物治疗的吸毒者和接受阿片类药物替代治疗者对直接作用抗病毒治疗的反应。
J Hepatol. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018. Epub 2019 Mar 8.
9
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.肝细胞癌会降低使用直接作用抗病毒药物成功治疗丙型肝炎病毒的几率。
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
10
Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.确定慢性丙型肝炎感染治疗的障碍。
Dig Dis. 2020;38(1):46-52. doi: 10.1159/000501821. Epub 2019 Aug 16.

引用本文的文献

1
Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018-2023.2018 - 2023年城市学术医疗中心丙型肝炎治疗中的种族和社会人口学差异
Open Forum Infect Dis. 2025 Jun 13;12(6):ofaf312. doi: 10.1093/ofid/ofaf312. eCollection 2025 Jun.
2
Hepatitis C Treatment Initiation During Hospitalization for People Who Use Drugs: A Narrative Review of the Literature.住院期间吸毒者的丙型肝炎治疗启动:文献综述
Open Forum Infect Dis. 2025 Apr 24;12(6):ofaf237. doi: 10.1093/ofid/ofaf237. eCollection 2025 Jun.
3
Enhancing Hepatitis C Virus Testing, Linkage to Care, and Treatment Commencement in Hospitals: A Systematic Review and Meta-analysis.

本文引用的文献

1
Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.直接作用抗病毒治疗与医疗保险受益人群丙型肝炎死亡率的关联。
JAMA Netw Open. 2020 Jul 1;3(7):e2011055. doi: 10.1001/jamanetworkopen.2020.11055.
2
HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center.在一家学术医疗中心的不同地点进行 HCV 筛查、护理衔接和治疗模式。
PLoS One. 2019 Jul 10;14(7):e0218388. doi: 10.1371/journal.pone.0218388. eCollection 2019.
3
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
加强医院丙型肝炎病毒检测、与治疗的衔接及治疗启动:一项系统评价与荟萃分析
Open Forum Infect Dis. 2025 Feb 4;12(2):ofaf056. doi: 10.1093/ofid/ofaf056. eCollection 2025 Feb.
4
Missed Opportunities: A Retrospective Study of Hepatitis C Testing in Hospital Inpatients.错失的机会:医院住院患者丙型肝炎检测的回顾性研究。
Viruses. 2024 Jun 18;16(6):979. doi: 10.3390/v16060979.
5
Statin therapy impact on Long-Term outcomes in acute heart Failure: Retrospective analysis of hospitalized patients.他汀类药物治疗对急性心力衰竭长期预后的影响:住院患者的回顾性分析
Int J Cardiol Heart Vasc. 2024 May 20;53:101431. doi: 10.1016/j.ijcha.2024.101431. eCollection 2024 Aug.
6
Slicing through silos: Development and evaluation of a hospital-based telehealth hepatitis C virus treatment program.打破壁垒:基于医院的远程医疗丙型肝炎病毒治疗项目的开发与评估。
Int J Drug Policy. 2024 May;127:104396. doi: 10.1016/j.drugpo.2024.104396. Epub 2024 Apr 9.
7
Leave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital Inpatients.《一个不落:对医院住院患者丙型肝炎检测和与护理衔接的回顾性研究》。
Viruses. 2023 Mar 31;15(4):913. doi: 10.3390/v15040913.
8
Trends in fatal and nonfatal overdose by race among people who inject drugs in Baltimore, Maryland from 1998 to 2019.1998 年至 2019 年期间,马里兰州巴尔的摩市注射吸毒者的种族与致命和非致命过量用药趋势。
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109152. doi: 10.1016/j.drugalcdep.2021.109152. Epub 2021 Oct 30.
格卡瑞韦哌仑他韦治疗伴有精神障碍的慢性丙型肝炎病毒感染患者的疗效和安全性:一项综合分析。
J Viral Hepat. 2019 Aug;26(8):951-960. doi: 10.1111/jvh.13110. Epub 2019 May 20.
4
Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.估计 2013-2016 年美国丙型肝炎病毒感染的流行率。
Hepatology. 2019 Mar;69(3):1020-1031. doi: 10.1002/hep.30297. Epub 2018 Nov 6.
5
Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?在直接作用抗病毒治疗时期,精神健康或物质使用障碍患者获得丙型肝炎病毒治疗的机会是否发生了变化?
Hepatology. 2019 Jan;69(1):51-63. doi: 10.1002/hep.30171. Epub 2018 Dec 18.
6
Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.丙型肝炎治疗的成本效益:它并不随着持续病毒学应答而结束。
Dig Dis Sci. 2018 Jun;63(6):1376-1377. doi: 10.1007/s10620-018-5014-7.
7
Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.丙型肝炎治愈与退伍军人事务回顾性队列中肝硬化患者的医疗保健费用降低有关。
Dig Dis Sci. 2018 Jun;63(6):1454-1462. doi: 10.1007/s10620-018-4956-0. Epub 2018 Feb 16.
8
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.索磷布韦和维帕他韦治疗近期有注射吸毒史的丙型肝炎病毒感染(SIMPLIFY):一项开放标签、单臂、4 期、多中心试验。
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.
9
Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs.治愈丙型肝炎病毒感染:美国退伍军人事务部的最佳实践。
Ann Intern Med. 2017 Oct 3;167(7):499-504. doi: 10.7326/M17-1073. Epub 2017 Sep 26.
10
Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.直接抗病毒药物时代丙型肝炎治疗的障碍
Aliment Pharmacol Ther. 2017 Nov;46(10):992-1000. doi: 10.1111/apt.14328. Epub 2017 Sep 26.